Literature DB >> 11179750

Selective inhibition of vitamin D hydroxylases in human keratinocytes.

I Schuster1, H Egger, D Bikle, G Herzig, G S Reddy, A Stuetz, P Stuetz, G Vorisek.   

Abstract

Human keratinocytes convert 25(OH)D(3) to hormonally active 1alpha,25(OH)(2)D(3) and respond to its antiproliferative/prodifferentiating action in vitro and in vivo. Levels and activity of 1alpha,25(OH)(2)D(3) are short-lived. 1alpha,25(OH)(2)D(3) induces 24-hydroxylase (CYP24) that rapidly metabolizes the hormone, yielding a cascade of side-chain oxidized products and this eventually results in the loss of activity. Aiming at stabilizing the levels of active hormone, we have searched for potent, selective inhibitors of CYP24. Selective inhibition was crucial in order to avoid impairment of 1alpha,25(OH)(2)D(3) synthesis, catalyzed by 1alpha-hydroxylase - a related member of cytochrome P-450 (CYP) superfamily. We describe here the testing protocol, using primary human keratinocyte cultures as an appropriate source of CYP24 and 1alpha-hydroxylase, (3)H-25(OH)D(3) (at physiological concentrations) as substrate and sensitive HPLC techniques to analyze the complex metabolite profiles. Four hundred potential inhibitors were screened by this method; most of them were synthesized in our laboratory. These compounds (entitled azoles) were capable of direct binding to the heme iron and of additional interactions with other parts of the enzyme. In this paper, we present VID400 and SDZ 89-443, as first examples of powerful selective CYP24 inhibitors. As anticipated, these compounds increased the levels of 1alpha-hydroxylated products generated from (3)H-25(OH)D(3) and extended their lifetime. Importantly, blocking of 24-hydroxylation led to a switch in metabolism, namely to preferential conversion of 1alpha,25(OH)(2)D(3) to 1alpha,25(OH)(2)-3epi-D(3). As spin-off from our program, selective inhibitors of 1alpha-hydroxylase were also found (e.g. SDZ 88-357). Using (3)H-25(OH)D(3) as substrate in the absence of SDZ 88-357, CYP24 showed high preference for freshly generated 1alpha-hydroxylated metabolites over abundant 25(OH)D(3). In the presence of SDZ 88-357, we noticed a great increase in 24-hydroxylation of (3)H-25(OH)D(3). Besides their use as valuable tools in elucidating regulatory mechanisms, inhibitors of VD hydroxylases may give rise to novel therapeutic strategies, especially in defects of cell growth and differentiation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179750     DOI: 10.1016/s0039-128x(00)00159-8

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  16 in total

1.  Synthesis and biological activities of vitamin D-like inhibitors of CYP24 hydroxylase.

Authors:  Grazia Chiellini; Simona Rapposelli; Jinge Zhu; Ilaria Massarelli; Marilena Saraceno; Anna Maria Bianucci; Lori A Plum; Margaret Clagett-Dame; Hector F DeLuca
Journal:  Steroids       Date:  2011-11-25       Impact factor: 2.668

Review 2.  Vitamin D and the kidney.

Authors:  Rajiv Kumar; Peter J Tebben; James R Thompson
Journal:  Arch Biochem Biophys       Date:  2012-03-15       Impact factor: 4.013

Review 3.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

4.  Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs.

Authors:  Kenneth M Rassnick; Josephia R Muindi; Candace S Johnson; Dennis B Bailey; Donald L Trump
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-21       Impact factor: 3.333

Review 5.  Investigating metabolite-protein interactions: an overview of available techniques.

Authors:  Grace Xiaolu Yang; Xiyan Li; Michael Snyder
Journal:  Methods       Date:  2012-06-28       Impact factor: 3.608

Review 6.  Studies of metabolite-protein interactions: a review.

Authors:  Ryan Matsuda; Cong Bi; Jeanethe Anguizola; Matthew Sobansky; Elliott Rodriguez; John Vargas Badilla; Xiwei Zheng; Benjamin Hage; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-11-25       Impact factor: 3.205

Review 7.  Vitamin D metabolism, mechanism of action, and clinical applications.

Authors:  Daniel D Bikle
Journal:  Chem Biol       Date:  2014-02-13

8.  The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis.

Authors:  Henrik C Horváth; Péter Lakatos; János P Kósa; Krisztián Bácsi; Katalin Borka; Giovanna Bises; Thomas Nittke; Pamela A Hershberger; Gábor Speer; Enikö Kállay
Journal:  J Histochem Cytochem       Date:  2009-11-09       Impact factor: 2.479

Review 9.  Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.

Authors:  Robert D Bruno; Vincent C O Njar
Journal:  Bioorg Med Chem       Date:  2007-05-23       Impact factor: 3.641

Review 10.  Hepatic actions of vitamin D receptor ligands: a sunshine option for chronic liver disease?

Authors:  Ning Ding; Christopher Liddle; Ronald M Evans; Michael Downes
Journal:  Expert Rev Clin Pharmacol       Date:  2013-11       Impact factor: 5.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.